Wir verwenden Cookies und Analyse-Tools, um die Nutzerfreundlichkeit der Internet-Seite zu verbessern und für Marketingzwecke. Wenn Sie fortfahren, diese Seite zu verwenden, nehmen wir an, dass Sie damit einverstanden sind. Zur Datenschutzerklärung.
Renzapride
CHF 37.40
Auf Lager
SKU
VOUK688I4LP
1 Verfügbar 
Geliefert zwischen Fr., 14.11.2025 und Mo., 17.11.2025
Details
Please note that the content of this book primarily consists of articles available from Wikipedia or other free sources online. Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT4 full agonist and 5-HT3 antagonist. It also functions as a 5-HT2B antagonist and has some affinity for the 5-HT2A and 5-HT2C receptors, though it is unlikely that these properties contribute to its therapeutic effects. Renzapride was being developed by Alizyme plc of the United Kingdom. Renzapride was being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme plc of the United Kingdom. As of 23 April 2008, Alizyme ceased all development of renzapride, after a Phase III trial in the U.S. did not show enough efficacy over placebo to justify further development.
Weitere Informationen
- Allgemeine Informationen
- GTIN 09786130967727
- Editor Lambert M. Surhone, Miriam T. Timpledon, Susan F. Marseken
- Genre Chemie
- Größe H220mm x B220mm
- EAN 9786130967727
- Format Fachbuch
- Titel Renzapride
- Herausgeber Betascript Publishing
- Anzahl Seiten 72
Bewertungen
Schreiben Sie eine Bewertung
